Home MacuLogix: Dark Adaptation and AMD On Our Way to Better Days

On Our Way to Better Days

How technology takes the guesswork out of monitoring and managing AMD suspects

By Jessica Haynes, OD

In primary care optometric practice, most doctors frequently engage with patients with subclinical, early, intermediate age-related macular degeneration (AMD) and even advanced non-exudative AMD, but in our retina clinic, we typically manage a very different demographic. While we occasionally get to manage patients with early or intermediate disease, more often, we’re treating advanced-stage exudative AMD patients who need anti-VEGF treatment. What’s worse is that too many of these patients come in with a fresh diagnosis and 20/200 vision—at which point it can be extremely challenging bring their vision back. The injections help, but they can’t undo all that damage.

Meeting a new patient who doesn’t yet have AMD-related vision loss makes for a great clinic day. And sometimes (although not as often as I would like) I get to see choroidal neovascularization (CNV) patients who present with 20/20 vision. When this happens, I’m so grateful to the referring doctor because I believe we can make a big difference in that patient’s quality of life. The million-dollar question is: How can all primary care optometrists help make these timely referrals the norm rather than the exception?

One challenge in primary eye care is lack of access to the range of tools needed to make fully-informed decisions that help guide early intervention and prompt referrals. That makes it really hard. None of us want to rely on what we think instead of what we know—especially when we’re treating a potentially blinding disease. Yet this is often the reality.

If your practice has access to technologies such as OCT, FAF, OCT-A, and dark adaptation (commercially available as AdaptDx by MacuLogix), you have a much more reliable compass to help navigate decision-making, and it’s a lot easier to decide whether it’s time for vitamin supplementation, home monitoring devices such as Notal Vision’s ForeseeHome system, or for a referral to a retinal specialist. Each of these tools provides unique insight into the disease. In combination, they paint a more complete picture of AMD, allowing us to better identify who is at higher risk of conversion to advanced stage disease, and detect that conversion earlier. Without these tools, we have to rely exclusively on what we can see—and although careful fundus evaluation remains crucial, ancillary testing allows us to see what’s happening beneath the surface and alert us to clinically unseen threats to vision.

In our clinic, I get a baseline OCT and FAF on every patient, which helps me detect disease that can’t be seen clinically (Figure 1 and 2). These tools alongside dark adaptation in the primary care setting, may alert the primary care optometrist of a more advanced disease process than is clinically visible.

Figure 1: A patient with numerous small- to medium-sized drusen demonstrates reticular pseudodrusen (RPD) on FAF (reticular pattern of altered autofluorescence) and OCT (hyper-reflective projections above the RPE shown by blue arrows). Patients with RPD have increased risk of developing advanced stage disease and should be monitored more carefully. Patients with RPD also tend to have worse visual function, more visual complaints and worse dark adaptation.

Indeed, I am encouraged that there seems to be a trend toward increased adoption of these technologies, and, with that in mind, I would recommend that my colleagues make as much use of them as possible because they really can make a big difference for our patients. The key is in putting everything together. If you don’t see any drusen, but a dark adaptation evaluation reveals a problem, you know you should run an OCT to evaluate more carefully the outer retina, retinal pigment epithelium and choroid. This becomes a very easy decision. If the OCT is abnormal, it’s potentially time to start considering supplements and perhaps even prescribe the ForeseeHome system if there is evidence of intermediate stage AMD.

Figure 2: AMD follow up with serial OCT reveals new intraretinal fluid (blue arrow) overlying an elongated pigment epithelial detachment (red arrow). This may be suggestive of exudative AMD and should be investigated further with OCT-A, IVFA or referral to a retina specialist. This is finding was not visible clinically.

If the OCT is normal, care should still be taken to advise these patients about important lifestyle modifications to reduce their risk of developing clinically visible AMD, and ultimately reduce their risk of vision loss from AMD. Testing should be looked at comprehensively to paint a bigger picture of the disease. This is a thoughtful and medically oriented approach to optometric practice. Each test informs the next and all of them combined dictate the recommendation we make to the patient.

There is no need to alarm patients nor to give them a false sense of security. Both of these scenarios are equally inadvisable. Indeed, the way to proceed with real confidence when managing patients who have not yet progressed to a stage with compromised vision is to take all the pieces of the puzzle—the OCT, FAF, OCT-A, dark adaptation and the fundus evaluation—and base your strategy on this more complete dataset.

Dr. Haynes is in practice at the Charles Retina Institute in Germantown, Tennessee.


- Advertisment -

Most Popular

Sights Turn to Summer With Three New Releases from The McGee Group

The McGee Group announced the release of its May lineup of eyewear, featuring Badgley Mischka, Trina Turk and Jenny Lynn Eyewear. These well-known lifestyle...

Student Loan Debt Strategies Evoke Both Pride and Pain

Many ODs responded to the WO Pop-up Poll on student loan debt. You can read the poll results here. Here are some of the individual...

Debt Is a Drain on Dreams for Some ODs

Ninety-six percent of respondents to a WO Pop-up Poll said that they graduated optometry school – or expect to – with student loan debt....